Compare Quest Diagnostics Inc (DGX) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Quest Diagnostics Inc trades at $237.46 (market cap $26.21B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.62. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| DGX | EMLC | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Fixed Income |
52-Week High | $238.50 | $26.59 |
52-Week Low | $173.49 | $24.83 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
EMLC trades at $25.655, up 0.14% with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent dividend distributions, with recent payouts of $0.14 in June 2026. Support and resistance cluster around $26, indicating a key price level. Financial ratios are not provided in the snapshot, limiting fundamental assessment.
Outlook hinges on emerging market debt dynamics and Federal Reserve policy, as noted in recent news. Risks include volatility from macroeconomic shifts and regional instability. The technical setup suggests near-term stability, but fundamental clarity is needed for long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
